MX2016014143A - Derivados de diheterociclo enlazado a cicloalquilo. - Google Patents

Derivados de diheterociclo enlazado a cicloalquilo.

Info

Publication number
MX2016014143A
MX2016014143A MX2016014143A MX2016014143A MX2016014143A MX 2016014143 A MX2016014143 A MX 2016014143A MX 2016014143 A MX2016014143 A MX 2016014143A MX 2016014143 A MX2016014143 A MX 2016014143A MX 2016014143 A MX2016014143 A MX 2016014143A
Authority
MX
Mexico
Prior art keywords
cycloalkyl
compounds
derivatives
linked
mammals
Prior art date
Application number
MX2016014143A
Other languages
English (en)
Inventor
Craig Burns Aaron
Raymond Collins Michael
Elizabeth Greasley Samantha
Louis Hoffman Robert
Huang Qinhua
Steven Kania Robert
Pei Kung Pei-
Angelica Linton Maria
Sourirajan Narasimhan Lakshmi
Francis Richardson Paul
Tyler Richter Daniel
Smith Graham
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016014143A publication Critical patent/MX2016014143A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención se refiere a compuestos de la fórmula (I) (ver Fórmula) o sales farmacéuticamente aceptables de los mismos, en donde A, L, D, R1-R15, w, x, y y z son como se define en la presente. Los derivados de diheterociclo ligados a cicloalquilo novedosos que son útiles en el tratamiento de crecimiento celular anormal, tal como cáncer, en mamíferos. La presente invención también se refiere a composiciones farmacéuticas que contienen los compuestos y a métodos de usar los compuestos y composiciones en el tratamiento de crecimiento celular anormal en mamíferos.
MX2016014143A 2014-04-30 2015-04-17 Derivados de diheterociclo enlazado a cicloalquilo. MX2016014143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986876P 2014-04-30 2014-04-30
PCT/IB2015/052833 WO2015166373A1 (en) 2014-04-30 2015-04-17 Cycloalkyl-linked diheterocycle derivatives

Publications (1)

Publication Number Publication Date
MX2016014143A true MX2016014143A (es) 2017-02-15

Family

ID=53276932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014143A MX2016014143A (es) 2014-04-30 2015-04-17 Derivados de diheterociclo enlazado a cicloalquilo.

Country Status (41)

Country Link
US (4) US20170050958A1 (es)
EP (2) EP3137460B1 (es)
JP (2) JP6574203B2 (es)
KR (1) KR20160149256A (es)
CN (1) CN106232598B (es)
AP (1) AP2016009530A0 (es)
AU (1) AU2015254943B2 (es)
BR (1) BR112016024513A2 (es)
CA (1) CA2947130C (es)
CL (1) CL2016002532A1 (es)
CR (1) CR20160497A (es)
CU (1) CU24420B1 (es)
CY (1) CY1122439T1 (es)
DK (1) DK3137460T3 (es)
DO (1) DOP2016000293A (es)
EA (1) EA033919B1 (es)
EC (1) ECSP16083017A (es)
ES (1) ES2759434T3 (es)
GE (1) GEP20186879B (es)
GT (1) GT201600232A (es)
HK (1) HK1232212A1 (es)
HR (1) HRP20192056T1 (es)
HU (1) HUE046518T2 (es)
IL (1) IL248629B (es)
LT (1) LT3137460T (es)
MA (2) MA49708A (es)
MD (1) MD20160111A2 (es)
MX (1) MX2016014143A (es)
NI (1) NI201600163A (es)
NZ (1) NZ725496A (es)
PE (1) PE20161436A1 (es)
PH (1) PH12016501997B1 (es)
PL (1) PL3137460T3 (es)
PT (1) PT3137460T (es)
RS (1) RS59617B1 (es)
SG (1) SG11201608634RA (es)
SI (1) SI3137460T1 (es)
SV (1) SV2016005310A (es)
TN (1) TN2016000459A1 (es)
UA (1) UA117861C2 (es)
WO (1) WO2015166373A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015101958A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel inhibitors of glutaminase
BR112016024513A2 (pt) 2014-04-30 2017-08-15 Pfizer derivados de di-heterociclo ligados à cicloalquila
CN107474024B (zh) * 2016-06-08 2022-12-13 北京赛林泰医药技术有限公司 一种谷氨酰酶抑制剂及其组合物和用途
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH09104838A (ja) 1995-10-09 1997-04-22 Mitsui Toatsu Chem Inc 水性塗料用樹脂組成物
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP3299975B2 (ja) 1996-07-18 2002-07-08 ファイザー・インク マトリックスメタロプロテアーゼのホスフィン酸塩ベース阻害薬
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE272640T1 (de) 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
IL131042A (en) 1997-02-03 2004-07-25 Pfizer Prod Inc Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
TR199901926T2 (xx) 1997-02-11 1999-12-21 Pfizer Inc. Arils�lfonil hidroksamik asit t�revleri
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EP1082305A4 (en) 1998-05-29 2001-09-26 Sugen Inc PYRROL SUBSTITUTED 2-INDOLINONE EFFECTIVE AS A PROTEIN KINASE INHIBITOR
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
YU95102A (sh) 2000-06-22 2005-11-28 Pfizer Products Inc. Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10109807A1 (de) 2001-03-01 2002-09-05 Wella Ag Verbrückte Diaminopyrazole und diese Verbindungen enthaltende Färbemittel
US7029729B2 (en) 2003-02-24 2006-04-18 3M Innovative Properties Company Cholesteric liquid crystal additives
ES2279446T3 (es) 2003-08-15 2007-08-16 MERCK & CO., INC. Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina.
CA2579889A1 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
WO2014031933A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
HRP20211610T1 (hr) 2012-11-16 2022-02-04 Calithera Biosciences, Inc. Inhibitori heterocikličke glutaminaze
ES2761951T3 (es) 2012-11-21 2020-05-21 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de uso
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
BR112015012536A2 (pt) 2012-12-03 2017-07-11 Calithera Biosciences Inc tratamento de câncer com inibidores heterocíclicos da glutaminase
US9868705B2 (en) * 2013-09-27 2018-01-16 The Board Of Trustees Of The University Of Illinois Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015101958A2 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2015143340A1 (en) 2014-03-21 2015-09-24 Agios Pharmaceuticals, Inc. Compounds and their methods of use
BR112016024513A2 (pt) * 2014-04-30 2017-08-15 Pfizer derivados de di-heterociclo ligados à cicloalquila
US9687485B2 (en) 2014-06-13 2017-06-27 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
AU2016243631B2 (en) 2015-03-30 2021-07-29 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
KR20170132333A (ko) 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제에 의한 폐암의 치료
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
JP2019214597A (ja) 2019-12-19
CN106232598A (zh) 2016-12-14
WO2015166373A1 (en) 2015-11-05
CY1122439T1 (el) 2020-11-25
ES2759434T3 (es) 2020-05-11
GEP20186879B (en) 2018-07-10
ECSP16083017A (es) 2017-03-31
IL248629A0 (en) 2017-01-31
EP3137460B1 (en) 2019-10-23
HUE046518T2 (hu) 2020-03-30
US20190270737A1 (en) 2019-09-05
MA39926B1 (fr) 2019-12-31
KR20160149256A (ko) 2016-12-27
CU24420B1 (es) 2019-06-04
AP2016009530A0 (en) 2016-10-31
DOP2016000293A (es) 2016-12-30
MD20160111A2 (ro) 2017-06-30
NI201600163A (es) 2016-11-25
BR112016024513A2 (pt) 2017-08-15
HK1232212A1 (zh) 2018-01-05
CL2016002532A1 (es) 2017-04-21
EP3556757A1 (en) 2019-10-23
AU2015254943B2 (en) 2019-04-04
IL248629B (en) 2019-07-31
SI3137460T1 (sl) 2019-12-31
CR20160497A (es) 2016-12-20
NZ725496A (en) 2019-11-29
LT3137460T (lt) 2019-12-10
US10125130B2 (en) 2018-11-13
HRP20192056T1 (hr) 2020-02-21
GT201600232A (es) 2019-10-10
PT3137460T (pt) 2019-12-30
EA201650003A1 (ru) 2017-03-31
EP3137460A1 (en) 2017-03-08
PE20161436A1 (es) 2017-01-08
SG11201608634RA (en) 2016-11-29
JP2017514818A (ja) 2017-06-08
CA2947130A1 (en) 2015-11-05
EA033919B1 (ru) 2019-12-10
RS59617B1 (sr) 2020-01-31
MA49708A (fr) 2020-06-03
UA117861C2 (uk) 2018-10-10
CA2947130C (en) 2018-10-02
JP6574203B2 (ja) 2019-09-11
US20190040055A1 (en) 2019-02-07
PL3137460T3 (pl) 2020-04-30
US10676471B2 (en) 2020-06-09
US20170050958A1 (en) 2017-02-23
CU20160157A7 (es) 2017-05-10
US20180148441A1 (en) 2018-05-31
CN106232598B (zh) 2020-03-13
PH12016501997A1 (en) 2017-01-09
AU2015254943A1 (en) 2016-10-27
TN2016000459A1 (en) 2018-04-04
SV2016005310A (es) 2017-08-29
DK3137460T3 (da) 2019-12-16
PH12016501997B1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TW201613864A (en) Novel compounds
TN2017000031A1 (en) Imidazopyridazine compounds
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs